Question 21

Bleeding

Warfarin is an anticoagulant medication that increases the risk of bleeding, which is a significant and well-documented adverse effect. Patients on warfarin therapy must be closely monitored for any signs of excessive bleeding.

A) Hypoglycemia

Hypoglycemia is a condition characterized by abnormally low blood sugar levels and is not associated with warfarin. This option is incorrect as warfarin does not influence glucose metabolism or insulin secretion, which are the primary factors leading to hypoglycemia.

B) Bleeding

Bleeding is the correct answer as it is a direct consequence of the anticoagulant properties of warfarin. The medication inhibits vitamin K-dependent clotting factors, which can lead to increased bleeding risk, making careful monitoring essential for patients on this therapy.

C) Hypertension

Hypertension, or high blood pressure, is not an adverse effect of warfarin. This option is incorrect because warfarin does not have a direct impact on blood pressure regulation, and patients may experience hypertension due to unrelated factors.

D) Tachycardia

Tachycardia, or an elevated heart rate, is not a recognized adverse effect of warfarin. This option is incorrect as warfarin primarily affects blood coagulation rather than heart rate or rhythm.

Conclusion

Bleeding is a well-known adverse effect of warfarin due to its role as an anticoagulant, while the other options do not relate to the pharmacological action of this medication. Hypoglycemia, hypertension, and tachycardia are not caused by warfarin, making them incorrect choices in this context. Therefore, option B is definitively the correct answer.